Biovail, Procyon Fibrostat deal

Procyon (TSE:PBP) granted Biovail (BVF; TSE:BVF) U.S. marketing rights to Fibrostat, a topical tranglutaminase inhibitor cream to treat scarring. Under the agreement, PBP will receive a $4 million equ...